Ruth Ann Subach

Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: A randomized, double-blind, placebo-controlled, crossover study in healthy volunteers

David G. Soergel, Ruth Ann Subach, Nancy Burnham et al. · Pain · 2014 · 262 citations

Medicine, Pharmacokinetics, Pharmacology +17

A randomized, phase 2 study investigating TRV130, a biased ligand of the μ-opioid receptor, for the intravenous treatment of acute pain

Eugene R. Viscusi, Lynn R. Webster, Michael E. Kuss et al. · Pain · 2015 · 206 citations

Medicine, Pharmacology, Pharmacotherapy +17

A randomized, Phase IIb study investigating oliceridine (TRV130), a novel µ-receptor G-protein pathway selective (µ-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty

Neil Singla, Harold S. Minkowitz, David G. Soergel et al. · Journal of Pain Research · 2017 · 149 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

First Clinical Experience With TRV130: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

David G. Soergel, Ruth Ann Subach, Brian M. Sadler et al. · The Journal of Clinical Pharmacology · 2013 · 126 citations

Medicine, Clinical Pharmacokinetics, Pharmacology +15

First Clinical Experience with TRV027: Pharmacokinetics and Pharmacodynamics in Healthy Volunteers

David G. Soergel, Ruth Ann Subach, Conrad L. Cowan et al. · The Journal of Clinical Pharmacology · 2013 · 88 citations

Medicine, Pharmacokinetics, Pharmacology +15